{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:54:13Z","timestamp":1794300853639,"version":"4.9.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jcpo.2022.100382","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T19:45:26Z","timestamp":1672429526000},"page":"100382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Remziye","family":"Zaim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Redekop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2022.100382_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jcpo.2022.100382_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jcpo.2022.100382_bib3","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/d41586-017-08702-7","article-title":"The benefits of immunotherapy combinations","volume":"552","author":"Schmidt","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jcpo.2022.100382_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2022.100382_bib5","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jcpo.2022.100382_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-21-2275","article-title":"Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors","volume":"28","author":"Palmer","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jcpo.2022.100382_bib7","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.jval.2020.08.339","article-title":"How should value be attributed to the constituent parts of combination immunotherapy in non-small cell lung cancer?","volume":"23","author":"Zaim","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jcpo.2022.100382_bib8","unstructured":"A. Briggs, A. Doyle, J. Schneider, An Attribution of Value Framework for Combination Therapies. Report by the Value Attribution Working Group, 2021. \u3008https:\/\/www.takeda.com\/49a844\/siteassets\/en-gb\/home\/what-we-do\/combination-treatments\/a-value-attribution-framework-for-combination-therapies-takeda-whitepaper.pdf\u3009."},{"key":"10.1016\/j.jcpo.2022.100382_bib9","unstructured":"Addressing Challenges in Access to Oncology Medicines. Analytical Report. OECD. \u3008https:\/\/www.oecd.org\/health\/health-systems\/Addressing-Challenges-in-Access-to-Oncology-Medicines-Analytical-Report.pdf\u3009 (Accessed 15 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib10","unstructured":"S. Davis, Assessing technologies that are not cost-effective at a zero price. NICE Decision Support Unit Report, 2014. \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310371\/pdf\/Bookshelf_NBK310371.pdf\u3009 (Accessed 1 Jun 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib11","first-page":"6","article-title":"How do we evaluate technologies that are not cost effective at a zero price?","author":"Davis","year":"2016","journal-title":"Value Outcomes Spotlight"},{"key":"10.1016\/j.jcpo.2022.100382_bib12","first-page":"331","article-title":"Not cost-effective at zero price: valuing and paying for combination therapies in cancer","volume":"21","author":"Latimer","year":"2021","journal-title":"Expert Rev. Pharm. Outcomes Res"},{"key":"10.1016\/j.jcpo.2022.100382_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12913-021-06425-0","article-title":"Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop","volume":"21","author":"Latimer","year":"2021","journal-title":"BMC Health Serv. Res"},{"key":"10.1016\/j.jcpo.2022.100382_bib14","doi-asserted-by":"crossref","unstructured":"A. Towse, M. Lothgren, L. Steuten, et al. Why we need a new outcomes-based value attribution framework for combination regimens in oncology. OHE Consulting Report, London. Office of Health Economics, 2021. \u3008https:\/\/www.ohe.org\/publications\/why-we-need-new-outcomes-based-value-attribution-framework-combination-regimens\u3009 (Accessed 2 January 2022).","DOI":"10.1016\/j.jval.2022.06.009"},{"key":"10.1016\/j.jcpo.2022.100382_bib15","unstructured":"The US Food and Drug Administration: Pembrolizumab, 2017.\u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-5\u201310-2017\u3009 (Accessed 1 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib16","unstructured":"The US Food and Drug Administration grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC, 2018.\u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic\u3009 (Accessed 1 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib17","unstructured":"The US Food and Drug Administration approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC, 2018.\u3008https:\/\/www.fda.gov\/drugs\/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc\u3009 (Accessed 1 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib18","unstructured":"The US Food and Drug Administration approves atezolizumab with chemotherapy and bevacizumab for first-line treatment of metastatic non-squamous NSCLC, 2018.\u3008https:\/\/www.fda.gov\/drugs\/fda-approves-atezolizumab-chemotherapy-and-bevacizumab-first-line-treatment-metastatic-non-squamous\u3009 (Accessed 1 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib19","unstructured":"The US Food and Drug Administration approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR\/ALK aberrations, 2019. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk\u3009 (Accessed 1 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib20","unstructured":"The US Food and Drug Administration approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression \u22651 %), 2020.\u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1\u3009 (Accessed 1 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib21","unstructured":"The US Food & Drug Administration. FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC, 2020.\u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc\u3009 (Accessed 14 January 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib22","unstructured":"The US Food and Drug Administration approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. 2022.\u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung\u3009 (Accessed 1 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib23","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jcpo.2022.100382_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcpo.2022.100382_bib25","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2022.100382_bib26","article-title":"Minimizing control group allocation in randomized trials using dynamic borrowing of external control data - an application to second line therapy for non-small cell lung cancer","volume":"16","author":"Dron","year":"2019","journal-title":"Conte Clin. Trials Commun."},{"key":"10.1016\/j.jcpo.2022.100382_bib27","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2022.100382_bib29","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2022.100382_bib30","unstructured":"Drug Pricing Lab. DrugAbacus Methods. \u3008https:\/\/www.drugpricinglab.org\/tools\/drug-abacus\/methods\/\u3009 (Accessed 1 June 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2022.100382_bib32","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jcpo.2022.100382_bib33","unstructured":"ClinicalTrials.gov: Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer or Small Cell Lung Cancer, 2018. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00527735\u3009."},{"key":"10.1016\/j.jcpo.2022.100382_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.580459","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab for advanced non-small-cell lung cancer","volume":"12","author":"Wan","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jcpo.2022.100382_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8787","article-title":"Cost-effectiveness of Nivolumab-Ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer","volume":"4","author":"Courtney","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2022.100382_bib36","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3389\/fonc.2020.01649","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer","volume":"10","author":"Hu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jcpo.2022.100382_bib37","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1007\/s12325-021-01788-6","article-title":"Cost-effectiveness of nivolumab plus ipilimumab combined with two cycles of chemotherapy as first-line treatment in advanced non-small cell lung cancer","volume":"38","author":"Peng","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jcpo.2022.100382_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.573852","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced non-small-cell lung cancer","volume":"12","author":"Hao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jcpo.2022.100382_bib39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2217\/imt-2020-0112","article-title":"Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC","volume":"12","author":"Li","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jcpo.2022.100382_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760686","article-title":"Cost-effectiveness of nivolumab plus ipilimumab with and without chemotherapy for advanced non-small cell lung cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jcpo.2022.100382_bib41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.healthpol.2019.07.009","article-title":"Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology","volume":"123","author":"Dank\u00f3","year":"2019","journal-title":"Health Policy"},{"key":"10.1016\/j.jcpo.2022.100382_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1705035","article-title":"The economics of indication-based drug pricing","volume":"377","author":"Chandra","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jcpo.2022.100382_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40258-018-0377-7","article-title":"Multi-indication and combination pricing and reimbursement of pharmaceuticals: opportunities for improved health care through faster uptake of new innovations","volume":"16","author":"Persson","year":"2018","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.jcpo.2022.100382_bib44","unstructured":"T. Podkonjak, H. Taylor, B. Morgan et al. Voluntary Arbitration Framework for Combination Therapies. A proposed process by the Voluntary Arbitration Working Group, 2021. \u3008https:\/\/www.takeda.com\/4a81d5\/siteassets\/en-gb\/home\/what-we-do\/combination-treatments\/voluntaryarbitrationframeworkforcombinationtherapies_takedawhitepaper_september2021.pdf\u3009 (Accessed 1 Jun 2022)."},{"key":"10.1016\/j.jcpo.2022.100382_bib45","article-title":"Independent drug action and its statistical implications for development of combination therapies","volume":"98","author":"Chen","year":"2020","journal-title":"Conte Clin. Trials"},{"key":"10.1016\/j.jcpo.2022.100382_bib46","article-title":"Independent action models and prediction of combination treatment effects for response rate, duration of response and tumor size change in oncology drug development","volume":"106","author":"Sun","year":"2021","journal-title":"Conte Clin. Trials"},{"key":"10.1016\/j.jcpo.2022.100382_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20833","article-title":"Assessment of clinical activity of PD-1 checkpoint inhibitor combination therapies reported in clinical trials","volume":"3","author":"Schmidt","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2022.100382_bib48","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50036","article-title":"A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity","volume":"8","author":"Palmer","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.jcpo.2022.100382_bib49","unstructured":"C. Henshall, A. Towse, Time to Tackle the Challenges around Combination Therapies for Cancer, 2021.\u3008https:\/\/www.ohe.org\/news\/time-tackle-challenges-around-combination-therapies-cancer\u3009."},{"key":"10.1016\/j.jcpo.2022.100382_bib50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jcpo.2022.100382_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.intimp.2017.05.019","article-title":"Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: a meta-analysis of randomized clinical trials","volume":"49","author":"Peng","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jcpo.2022.100382_bib52","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcpo.2022.100382_bib53","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.2026","article-title":"Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe","volume":"7","author":"Vokinger","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jcpo.2022.100382_bib54","series-title":"International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies","author":"Mulcahy","year":"2021"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538322000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538322000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:08:03Z","timestamp":1761988083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538322000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":53,"alternative-id":["S2213538322000613"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2022.100382","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2022.100382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100382"}}